Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Jul 15;26(14):3291-3294.
doi: 10.1016/j.bmcl.2016.05.050. Epub 2016 May 18.

Assessment of the anti-metastatic properties of sanguiin H-6 in HUVECs and MDA-MB-231 human breast cancer cells

Eun-Hwa Park  1 , Jun Yeon Park  2 , Hwa-Seung Yoo  3 , Jeong-Eun Yoo  4 , Hye Lim Lee  5
Affiliations

Assessment of the anti-metastatic properties of sanguiin H-6 in HUVECs and MDA-MB-231 human breast cancer cells

Eun-Hwa Park et al. Bioorg Med Chem Lett. .

Abstract

The anti-metastatic properties of sanguiin H-6 were examined in human umbilical vein vascular endothelial cells (HUVECs) and MDA-MB-231 human breast cancer cells. In HUVECs, sanguiin H-6 inhibited the density of migrated cells compared to that observed after treatment with the vehicle. In addition, sanguiin H-6 at a concentration of 6.25μM significantly blocked tube formation. Treatment with up to 25μM sanguiin H-6 had no effect on MDA-MB-231 cells, whereas treatment with 200μM sanguiin H-6 decreased cell viability. Sanguiin H-6 significantly decreased the expression levels of vascular endothelial growth factor (VEGF), phosphorylated Akt, and extracellular signal-regulated kinase 1/2 (ERK1/2) in MDA-MB-231 cells. These findings suggest that sanguiin H-6 is potentially useful as an anti-metastatic agent.

Keywords: Breast cancer; HUVEC; Metastasis; Sanguiin H-6; VEGF.

PubMed Disclaimer

Publication types

MeSH terms